It joins Woburn, Mass. drug maker BioVex, which also pulled its IPO. They are the latest in a string of withdrawals and postponements in the health care industry this month.
Asthmatx’s withdrawal, for one, will deal a blow to Vanguard, the struggling venture firm that has been hoping for a decent profit from its investment in Asthmatx. A weak IPO market is hurting its chances to do that.
VentureWire has a good summary here (sub required):
Asthmatx said it was pulling its IPO to “pursue alternative strategic options,” while most others, like BioVex Group, are withdrawing or postponing new issues citing market conditions.
Out of eight health-care related deals that have tried to debut so far this month, only three succeeded: LeMaitre Vascular Inc., Trubion Pharmaceuticals Inc., and Ivivi Technologies Inc. Trubion and Ivivi each squeaked out a 1% gain during their first day of trading, while medical-device maker LeMaitre Vascular Inc. priced below its expected range and declined in its first days of trading.
VentureBeatVentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative technology and transact. Our site delivers essential information on data technologies and strategies to guide you as you lead your organizations. We invite you to become a member of our community, to access:
- up-to-date information on the subjects of interest to you
- our newsletters
- gated thought-leader content and discounted access to our prized events, such as Transform 2021: Learn More
- networking features, and more